Compare Orion Office REIT Inc (ONL) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Orion Office REIT Inc vs TG Therapeutics Inc — how do they compare? Orion Office REIT Inc trades at $2.55 (market cap $151.74M), while TG Therapeutics Inc trades at $54.77 (market cap $8.53B). The key difference: TG Therapeutics Inc is far larger — about 56.2× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays a 3.01% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ONL | TGTX | |
|---|---|---|
Market Cap | $151.74M | $8.53B |
Sector | Real Estate | Health |
52-Week High | $3.00 | $59.06 |
52-Week Low | $1.93 | $26.94 |
Enterprise Value | $568.67M | $8.74B |
Dividend Yield | 3.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Orion Office REIT (ONL) trades at $2.66, down 1.85% on the day, with a bearish technical outlook and mixed fundamentals. The company reported a Q2 2026 earnings beat but continues to post significant net losses, with a negative net income margin of -65.66% in 2025. Despite a low price-to-book ratio of 0.24, indicating potential undervaluation, declining revenues and negative profitability metrics highlight ongoing challenges in its office property portfolio.
The outlook remains cautious due to persistent operational losses and high debt levels, though analyst sentiment is split evenly between Buy and Hold. Key risks include further revenue erosion and interest expense pressures, while potential catalysts hinge on successful portfolio repositioning and stabilized office demand as highlighted in recent earnings calls.
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
